For antibody drug conjugates to reach their full potential, developers should focus on addressing current challenges such as safety and efficacy.
Andreas Dreps
Advertisement
Senior VP and Global Head Drug Development Unit, ICON plc
Articles by Andreas Dreps
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The 10 Most Powerful Study KRIs in RBQM and GCP Issues They Can Prevent
2
What FDA Inspections Reveal About the Quality of APAC Clinical Trial Sites
3
ACT Brief: APAC Inspection Findings, RBQM Key Risk Indicators, and Head and Neck Cancer Approval
4
How China Cut Its Phase III Startup Timeline and What Drove the Change
5